Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
50
Not yet recruiting, industry sponsors, Immunology and inflammation, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting139
- Completed1,148
50 trials
Showing 1 to 25, recently updated first.
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid ArthritisNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07951086 · 96 participants (planned) · Start Jan 26, 2027 · Primary completion May 18, 2028
Drug: DDY391; Placebo · For: Rheumatoid Arthritis
- MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)Not yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07938606 · 24 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: MG-K10 humanized monoclonal antibody injection · For: Atopic Dermatitis
Sites: Shanghai, China
- A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07895524 · 60 participants (planned) · Start Nov 23, 2026 · Primary completion Oct 19, 2027
Drug: Methotrexate (MTX) · For: Rheumatoid Arthritis
- A Study of IPG11406 Tablets in Participants With Lupus NephritisPivotal-lookingNot yet recruiting
Nanjing Immunophage Biotech Co., LtdIndustry
NCT07937501 · 192 participants (planned) · Start Nov 20, 2026 · Primary completion Nov 20, 2028
Drug: IPG11406 tablet; placebo · For: Lupus Nephritis
Sites: Nanjing, China
- A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe PsoriasisPivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07933536 · 105 participants (planned) · Start Dec 3, 2026 · Primary completion Dec 2028
Drug: Risankizumab; ABBV-295 and 1 more · For: Moderate to Severe Psoriasis
- Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid ArthritisPivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07904754 · 250 participants (planned) · Start Dec 7, 2026 · Primary completion Jul 2029
Drug: ABBV-722; Upadacitinib · For: Rheumatoid Arthritis
- Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)Not yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07923773 · 88 participants (planned) · Start Feb 10, 2027 · Primary completion Dec 12, 2029
Drug: DDY391 · For: Moderate to Severe Psoriatic Arthritis
- This Study Will Evaluate the Effect and Safety of 626 in Patients With CLEPivotal-lookingNot yet recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT07900867 · 140 participants (planned) · Start Nov 2026 · Primary completion Dec 2028
Drug: Placebo · For: Cutaneous Lupus Erythematosus (CLE)
Sites: Nanjing, China; Beijing, China
- A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Coultreon BiopharmaIndustry
NCT07914231 · 100 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 30, 2027
Drug: COL-5671-PRO; Placebo · For: Plaque Psoriasis
Sites: Markham, Canada; Mississauga, Canada; Peterborough, Canada · 6 sites in all
- To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic DermatitisNot yet recruiting
Hemay Pharmaceutical PTY. LTD.Industry
NCT07877155 · 90 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 3, 2027
Drug: Hemay5394 group; Control group · For: Safety; Efficiency
Sites: Waitara, Australia
- Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).Not yet recruiting
Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.Industry
NCT07871669 · 30 participants (planned) · Start Mar 1, 2027 · Primary completion Mar 1, 2028
Drug: TRA16; Placebo · For: Enteric Hyperoxaluria
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard TherapyNot yet recruiting
AbelZeta Inc.Industry
NCT07729826 · 50 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 31, 2028
Drug: C-CAR168 · For: Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Autoimmune Diseases
- Phase 2 Trial of FT2109 for the Treatment of Psoriatic ArthritisPivotal-lookingNot yet recruiting
Forward TherapeuticsIndustry
NCT07869134 · 210 participants (planned) · Start Dec 2026 · Primary completion Oct 2027
Drug: FT2109 Dosing Regimen 1; FT2109 Dosing Regimen 2 and 1 more · For: Psoriatic Arthritis (PsA)
- A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune DiseasesNot yet recruiting
PfizerPfizer (PFE)
NCT07782450 · 54 participants (planned) · Start Nov 19, 2026 · Primary completion Feb 22, 2031
Drug: PF-08154225 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis; Idiopathic Inflammatory Myositis and 1 more
- A Study of JYP0066 Cream in Mild-to-Moderate Atopic DermatitisPivotal-lookingNot yet recruiting
Guangzhou JOYO Pharma Co., LtdIndustry
NCT07843290 · 160 participants (planned) · Start Sep 30, 2026 · Primary completion Aug 30, 2027
Drug: JYP0066 4% topical cream; 3% JYP0066 topical cream and 2 more · For: Atopic Dermatitis (AD)
- A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's StricturesPivotal-lookingNot yet recruiting
Redx Pharma LtdIndustry
NCT07832435 · 180 participants (planned) · Start Oct 1, 2026 · Primary completion Aug 31, 2028
Drug: High Dose; Low Dose and 1 more · For: Strictures Due to Crohn's Disease
- Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Enzychem Lifesciences CorporationIndustry
NCT06487000 · 150 participants (planned) · Start May 2027 · Primary completion Oct 2027
Drug: EC-18; Placebo EC-18 · For: Atopic Dermatitis
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT07784816 · 390 participants (planned) · Start Aug 31, 2026 · Primary completion Sep 30, 2029
Drug: TLL-018 tablets; TLL-018 tablets and 2 more · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic DermatitisNot yet recruiting
Helixon Biotechnology (Suzhou) Co., LtdIndustry
NCT07782476 · 67 participants (planned) · Start Sep 2026 · Primary completion Oct 2027
Drug: HXN6005; Placebo and 4 more · For: Health Adult Subjects; Atopic Dermatitis (AD)
Sites: Hangzhou, China
- A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07765628 · 120 participants (planned) · Start Aug 6, 2026 · Primary completion Feb 28, 2027
Drug: HS-20118; Placebo · For: Moderate to Severe Plaque Psoriasis
- A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus ErythematosusNot yet recruiting
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT07760155 · 40 participants (planned) · Start Sep 1, 2026 · Primary completion Mar 31, 2028
Drug: ESG206; ESG206 and 1 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Shenzhen, China; Zhongshan, China; Guilin, China · 20 sites in all
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque PsoriasisNot yet recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07758075 · 50 participants (planned) · Start Aug 2026 · Primary completion Jul 2027
Drug: SHR-1139; SHR-1139 and SHR-1139 pleacebo · For: Plaque Psoriasis
Sites: Changsha, China
- A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative ColitisNot yet recruiting
Pyrotech Therapeutics, Inc.Industry
NCT07747155 · 40 participants (planned) · Start Aug 2026 · Primary completion Dec 2027
Drug: PTT-621 Tablets · For: Ulcerative Colitis (UC)
Sites: Shanghai, China
- A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With PsoriasisNot yet recruiting
Xantho Biotechnology Co., LTDIndustry
NCT06620692 · 65 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: 5% GM-XANTHO [GM-XAN003]; Placebo · For: Psoriasis
- Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)Pivotal-lookingNot yet recruiting
Clarent Biopharma, Inc.Industry
NCT07706530 · 240 participants (planned) · Start Jul 2026 · Primary completion Feb 2027
Drug: CBP-0276 capsules 100mg; Placebo · For: Arthritic Psoriasis
Sites: Mexico City, Mexico
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.